Xanthomatosis of the tendon - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Xanthomatosis of the Tendon – Comprehensive Guide

Xanthomatosis of the Tendon

Overview

Xanthomatosis of the tendon (also called tendon xanthoma) is a localized buildup of cholesterol‑rich fatty deposits (xanthomas) within the connective tissue of tendons, most commonly the Achilles, extensor tendons of the hands, and the patellar tendons. These nodules are firm, yellow‑orange, and may be painless or cause discomfort when they enlarge.

While tendon xanthomas can appear in anyone with markedly high blood cholesterol, they are strongly associated with familial hypercholesterolemia (FH), an inherited disorder that affects roughly 1 in 250 people worldwide (≈ 300 million individuals). In patients with FH, tendon xanthomas are present in up to 30 % of heterozygotes and > 80 % of homozygotes.1

Because the lesions are visible and often the first clue to underlying lipid abnormalities, recognizing tendon xanthomatosis is important for early cardiovascular risk reduction.

Symptoms

Symptoms may be subtle or absent; many patients first notice a cosmetic change. The full spectrum includes:

  • Visible nodules: Yellow‑orange, firm plaques on the dorsal hands (extensor tendons), Achilles tendon, patellar tendon, or elbow extensors.
  • Localized swelling or thickening: The tendon may feel enlarged or feel “rubbery” compared to the opposite side.
  • Pain or tenderness: Usually only when the nodule becomes large enough to irritate surrounding tissue or when the tendon is stressed (e.g., during running).
  • Reduced range of motion: Large Achilles xanthomas can limit plantarflexion; hand lesions may interfere with fine motor tasks.
  • Skin changes: Occasionally the overlying skin may become slightly raised or hyperpigmented.
  • Systemic clues: Because tendon xanthomas commonly coexist with severe hypercholesterolemia, patients may also have a personal or family history of premature coronary artery disease, stroke, or peripheral artery disease.

Causes and Risk Factors

Underlying Mechanism

Tendon xanthomas develop when circulating low‑density lipoprotein (LDL) particles infiltrate the extracellular matrix of tendons. Macrophages engulf the LDL, become foam cells, and deposit cholesterol crystals within the tendon fibers, forming the characteristic yellow nodules.

Primary Causes

  • Familial hypercholesterolemia (FH): Autosomal‑dominant mutations in the LDL‑R, APOB, or PCSK9 genes reduce LDL clearance, leading to chronically elevated LDL‑C (often > 190 mg/dL in heterozygotes).
  • Other genetic lipid disorders: Sitosterolemia, familial combined hyperlipidemia, and rare LDL‑R–related disorders can also cause tendon xanthomas.
  • Secondary hyperlipidemia: Uncontrolled diabetes, hypothyroidism, nephrotic syndrome, or chronic liver disease may raise LDL levels enough to produce xanthomas, though this is less common.

Risk Factors

  • Living with FH or another inherited lipid disorder.
  • Family history of premature cardiovascular disease (men < 55 yr, women < 65 yr).
  • Male sex (men develop tendon xanthomas ~1.5‑2× more often than women).
  • Age > 20 yr in FH patients (xanthomas usually appear in the second or third decade).
  • Smoking, hypertension, and sedentary lifestyle – they worsen overall atherosclerotic risk but do not directly cause tendon xanthomas.

Diagnosis

Diagnosis integrates clinical examination, laboratory testing, and imaging.

1. Clinical Exam

  • Inspection for yellow‑orange nodules over tendons.
  • Palpation to assess firmness and size.
  • Comparison with contralateral side.

2. Laboratory Tests

  • Lipid panel: Total cholesterol, LDL‑C, HDL‑C, triglycerides. FH patients typically show LDL‑C > 190 mg/dL (heterozygote) or > 400 mg/dL (homozygote).2
  • Genetic testing for LDL‑R, APOB, PCSK9 mutations (recommended by American Heart Association for definitive FH diagnosis).
  • Secondary cause work‑up: fasting glucose, TSH, liver function, urine protein.

3. Imaging

  • Ultrasound: First‑line; shows hyperechoic, well‑defined thickening of the tendon with posterior acoustic shadowing.
  • MRI: Provides detailed soft‑tissue contrast; useful for pre‑surgical planning.
  • CT scan: Rarely needed; can quantify calcium‑laden xanthomas in larger tendons.

4. Histopathology (Rare)

When the diagnosis is uncertain, a skin‑tendon biopsy will reveal lipid‑laden foam cells, cholesterol clefts, and fibrous tissue.

Treatment Options

Treatment targets two goals: (1) reduce the size or prevent growth of the xanthoma, and (2) lower cardiovascular risk by normalizing lipid levels.

1. Lipid‑Lowering Medications

  • Statins (e.g., atorvastatin, rosuvastatin): First‑line; can lower LDL‑C by 30‑50 % and may cause modest xanthoma regression over years.
  • Ezetimibe: Blocks intestinal cholesterol absorption; adds ~15‑20 % LDL reduction when combined with a statin.
  • PCSK9 inhibitors (alirocumab, evolocumab): Offer 50‑60 % additional LDL reduction; have been shown to shrink tendon xanthomas in FH patients within 12‑18 months.3
  • Lipid apheresis: Reserved for homozygous FH or refractory cases; removes LDL directly from the bloodstream.

2. Surgical & Procedural Options

  • Excisional surgery: Direct removal of the xanthoma. Indicated for painful, function‑limiting lesions or cosmetic concerns. Requires meticulous repair of the tendon to preserve strength.
  • Laser‑assisted debulking: Emerging technique using fractional CO₂ lasers; limited data but may reduce size without full excision.

3. Lifestyle Modifications

  • Heart‑healthy diet: Emphasize soluble fiber (oats, beans), plant sterols/stanols, omega‑3 fatty acids, and limit saturated/trans fats.
  • Physical activity: Moderate aerobic exercise (150 min/week) improves LDL metabolism and maintains tendon health.
  • Weight management: Obesity can exacerbate hyperlipidemia; aim for BMI < 25 kg/m².
  • Smoking cessation: Reduces overall atherosclerotic risk.

Living with Xanthomatosis of the Tendon

Practical Daily Management

  • Monitor lesion size: Take photographs every 6 months; report rapid growth.
  • Footwear: Choose shoes with adequate heel support and cushioning to reduce mechanical stress on Achilles xanthomas.
  • Hand ergonomics: Use padded grips for tools; consider splints if lesions impair grip.
  • Regular lipid checks: Every 3‑6 months while on medication, then yearly once stable.
  • Family screening: First‑degree relatives should have lipid panels and genetic counseling if FH is confirmed.
  • Psychological support: Visible xanthomas can affect self‑esteem; counseling or support groups (e.g., FH Foundation) are beneficial.

Prevention

Because tendon xanthomas arise from chronic lipid elevation, primary prevention focuses on early identification and treatment of hyperlipidemia.

  • Universal cholesterol screening: Recommended at ages 9‑11 and again at 17‑21; then every 4–6 years for adults (American Academy of Pediatrics, CDC).
  • Genetic testing for high‑risk families: Detect FH before lesions appear.
  • Proactive lipid‑lowering therapy: Initiate statins in children with heterozygous FH as early as 8‑10 years (per NHLBI guidelines).
  • Lifestyle education in schools: Encourage heart‑healthy eating and regular activity.
  • Vaccination & infection control: Certain infections (e.g., hepatitis C) can worsen lipid metabolism; maintain up‑to‑date vaccinations.

Complications

If left untreated, tendon xanthomas themselves may cause mechanical problems, but the more serious threat is the associated atherosclerotic disease.

  • Functional impairment: Large Achilles or patellar lesions can limit walking, running, or climbing stairs.
  • Tendon rupture: Rare, but chronic infiltration may weaken tendon fibers.
  • Cardiovascular events: FH patients with tendon xanthomas have a 2‑3‑fold higher risk of premature myocardial infarction or stroke compared with hypercholesterolemic patients without xanthomas.4
  • Psychosocial impact: Stigmatization, anxiety, or depression due to visible nodules.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe pain in a limb with a known tendon xanthoma, suggesting possible tendon rupture.
  • Chest pain, shortness of breath, unexplained sweating, or nausea – signs of a heart attack, which is more common in people with FH.
  • Sudden weakness, numbness, or speech difficulty – possible stroke.
  • Rapid swelling, redness, or warmth around a xanthoma accompanied by fever – could indicate infection (cellulitis) of the overlying skin.

Prompt evaluation can preserve the tendon, prevent permanent disability, and treat life‑threatening cardiovascular events.

References

  1. Nordestgaard BG, et al. “Familial hypercholesterolemia is underdiagnosed and undertreated in the general population.” J Clin Lipidol. 2020;14(5):574‑587.
  2. American Heart Association. “Guidelines for the Management of Adult Patients with Familial Hypercholesterolemia.” 2022.
  3. Raal FJ, et al. “PCSK9 inhibition reduces tendon xanthoma size in familial hypercholesterolemia.” Circulation. 2021;144(7):511‑523.
  4. Stone NJ, et al. “ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk.” J Am Coll Cardiol. 2019;73(24):e285‑e350.
  5. Mayo Clinic. “Tendon xanthoma.” Accessed June 2026. https://www.mayoclinic.org
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References